Hostname: page-component-cd9895bd7-dzt6s Total loading time: 0 Render date: 2024-12-22T21:33:43.418Z Has data issue: false hasContentIssue false
  • English
  • Français

Visual release hallucinations presenting as psychosis – a scoping review

Published online by Cambridge University Press:  21 November 2024

Nicholas Bonomo Open the ORCID record for Nicholas Bonomo [Opens in a new window] ,
Ben Schoenbachler  and
Steven Lippmann
Nicholas Bonomo*
Affiliation:
School of Medicine, Department of Psychiatry and Behavioral Sciences, University of Louisville, Louisville, KY, USA
Ben Schoenbachler
Affiliation:
School of Medicine, Department of Psychiatry and Behavioral Sciences, University of Louisville, Louisville, KY, USA
Steven Lippmann
Affiliation:
School of Medicine, Department of Psychiatry and Behavioral Sciences, University of Louisville, Louisville, KY, USA
*
Corresponding author: Nicholas Bonomo; Email: [email protected]
Rights & Permissions [Opens in a new window]

Abstract

Objective

Visual release hallucinations are perceptual disturbances that occur in individuals who have experienced vision loss. Almost 50 million people worldwide are believed to experience visual release hallucinations, yet they are profoundly underdiagnosed. Although first described within the Charles Bonnet syndrome, the paradigm underlying this syndrome precludes their consideration in many populations, such as those with underlying psychiatric illness or dementia. Consequently, visual release hallucinations have rarely been studied in patients presenting with psychosis. We conducted a scoping review to determine whether visual-release hallucinations occur in psychotic patients.

Methods

The PubMed research database was searched from inception through April 2023. Cases were collected reporting on psychotic patients experiencing suspected visual release hallucinations. Individual treatment courses and responses were extracted.

Results

Thirteen cases compiled from 11 different studies were summarized to provide baseline characteristics and overall trends in treatment response. Most patients did not remit from pharmacological management alone. All patients who received reafferentation therapy remitted, though many were not candidates. Almost half of the patients did not achieve remission.

Conclusions

Visual release hallucinations can manifest in psychosis and may contribute to treatment-resistant psychosis among psychiatric populations. A shift in our understanding of visual release hallucinations may aid their recognition in psychotic patients by shifting the focus toward visual release features. Recognizing release features among patients with hallucinatory conditions may open new treatment avenues for managing patients with psychosis. A preliminary screening index for visual release features is provided to support this shift.

Keywords

Visual release hallucinationsCharles Bonnet syndromeneuromodulationtreatment-resistant psychosisrelease features
Type
Review
Information
CNS Spectrums , First View , pp. 1 - 7
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2024. Published by Cambridge University Press

Introduction

History

Visual release hallucinations (VRH) are neuropsychiatric phenomena that were first characterized under the Charles Bonnet syndrome (CBS).Reference Rojas and Gurnani 1 In 1760, the Swiss naturalistic philosopher Charles Bonnet described the emergence of visual hallucinations following vision loss in his grandfather and later in himself.Reference Pang 2 The condition was not named until 1967 after a case series was published by De Morsier calling it the Charles Bonnet syndrome (CBS).Reference Pang 2 The diagnostic criteria for CBS have been debated ever since.Reference Pang 2 , Reference Hamedani and Pelak 3 Even after 250 years, no formal guidelines are universally accepted for diagnosing CBS.Reference Hamedani and Pelak 3 Suggested diagnostic criteria for the condition include age, type of hallucination, insight, and absence of the following – cognitive impairment, delusions, hallucinations in other sensory domains, psychiatric history, as well as hallucinogenic drug exposure.Reference Hamedani and Pelak 3 The most common diagnostic criteria recognized for CBS are vision loss, the presence of formed-complex hallucinations, and preservation of insight, but even this set of criteria is rejected by more than half of clinicians.Reference Hamedani and Pelak 3 Table 1 depicts the historical variability amongst CBS diagnostic criteria.

Table 1. Charles Bonnet syndrome criteria

The conceptualization of CBS remains ambiguous.Reference Hamedani and Pelak 3 Under most diagnostic schemas it does not recognize VRH that occur in psychotic patients or is comorbid with other hallucinatory conditions.Reference Hamedani and Pelak 3 Consequentially, recognition of VRH in psychiatric populations is limited using the CBS paradigm. Given its ambiguity and anachronistic restrictiveness, the authors suggest we abandon the eponym of CBS. For clarity, “CBS” will be replaced with “VRH” henceforth.

Epidemiology

The lifetime prevalence of VRH in patients after vision loss is highly debated.Reference Pang 2 In one meta-analysis, VRH occurred in ~20% of cases with visual impairment, leading to an estimated global prevalence of 47 million people.Reference Subhi, Schmidt, Bach-Holm, Kolko and Singh 4 Still, estimates in other studies range from 0.4% to 30%.Reference Pang 2 There are many potential causes for this variability. One reason may be inadequate screening, as research has shown that patients rarely disclose release phenomena due to the stigma of being implicated as psychotic.Reference Rojas and Gurnani 1 Another cause may be variability in diagnostic criteria. For example, some diagnostic paradigms do not allow for VRH in patients with dementia and neurocognitive disorders.Reference Hamedani and Pelak 3 However, given that VRH directly correlate with cognitive impairment, social isolation, and low sensory environments they may be a common cause for nocturnal agitation in dementia termed “sundowning”.Reference Rojas and Gurnani 1 Whether or not dementia patients are included when estimating VRH prevalence may contribute substantially to inter-study variations.

To establish accurate prevalence estimates authors must not only consider all the populaces in which VRH occur but also their variable manifestations. VRH has traditionally been limited to complex hallucinations, yet evidence suggests they may be simple phenomena as well.Reference Rojas and Gurnani 1 -Reference Hamedani and Pelak 3 Simple hallucinations, which are also referred to as elementary or unformed; consist of photopsias, basic shapes, grid-like designs, and branching patterns.Reference Pang 2 Complex hallucinations are formed, vivid images of people, faces, vehicles, animals, plants, and objects.Reference Pang 2 Complex VRH is often qualified as “Lilliputian”, meaning the image perceived is distortedly smaller than it would be experienced if witnessed directly from the external world.Reference Vojniković, Radeljak, Dessardo, Zarković-Palijan, Bajek and Linsak 5 Ultimately, VRH present with a spectrum of manifestations across many different populaces.

Pathophysiology

VRH are release phenomena that develop following sensory deafferentation.Reference Marschall, Brederoo, Ćurčić-Blake and Sommer 6 Deafferentation is an interruption or destruction of an afferent nerve pathway.Reference Marschall, Brederoo, Ćurčić-Blake and Sommer 6 This deafferentation may be transient or chronic and can occur due to damage at any point in the sensory pathway.Reference Rojas and Gurnani 1 , Reference Marschall, Brederoo, Ćurčić-Blake and Sommer 6 Consequentially, there are numerous conditions that provoke VRH.Reference Rojas and Gurnani 1 Common pathologies include glaucoma, cataracts, myopia, diabetic retinopathy, macular degeneration, retinitis pigmentosa, optic neuritis, temporal arteritis, retinal vein or central retinal arterial occlusions, and cerebral/occipital infarctions.Reference Rojas and Gurnani 1

Following deafferentation, the brain undergoes several pathological changes. Single-photon emission computed tomography (SPECT) studies provide evidence that deafferentation is associated with hypo-perfusion of the primary and secondary visual cortices and hyper-perfusion of the striatum and thalamus.Reference Marschall, Brederoo, Ćurčić-Blake and Sommer 6 Positron emission tomography (PET) imaging reveals similar patterns related to metabolic disturbances.Reference Marschall, Brederoo, Ćurčić-Blake and Sommer 6 Functional magnetic resonance imaging (fMRI) studies have shown that visual deafferentation is associated with hyperexcitability in the visual cortex and salience network, and increased connectivity between the visual cortex and other cortical regions.Reference Marschall, Brederoo, Ćurčić-Blake and Sommer 6 Increased activity of brain regions that correlate with the type of VRH are also described, for example, increased activity at the fusiform nucleus in patients experiencing VRH involving faces.Reference Marschall, Brederoo, Ćurčić-Blake and Sommer 6 Collectively this research suggests that incoming afferent tone normally exerts an inhibitory effect on the sensory cortex.Reference Marschall, Brederoo, Ćurčić-Blake and Sommer 6 Following deafferentation, cortical disinhibition and hyperexcitability allow for the provocation of release phenomena.Reference Marschall, Brederoo, Ćurčić-Blake and Sommer 6 Whether release phenomena are provocations of latent hallucinations, exacerbations of pre-existing hallucinatory conditions or a sufficient independent risk factor unto itself for hallucinations remains unclear (Figure 1).

Figure 1. A simplified model for a deafferentation injury. The top diagram depicts a normal visual pathway, and the bottom depicts a visual pathway with a deafferentation injury secondary to ocular pathology. The solid lines indicate an intact sensory pathway, while the dotted lines indicate deafferentation. Changes in blood flow (red arrow), metabolism (orange arrow) and excitability (yellow arrow) are denoted.

Management

Reafferentation therapy

Minimizing deafferentation is the standard treatment for VRH.Reference Rojas and Gurnani 1 , Reference Marschall, Brederoo, Ćurčić-Blake and Sommer 6 Initial strategies optimize residual vision via spectacles, contact lenses, optical aids, and/or low-vision rehabilitation.Reference Hamedani and Pelak 3 , Reference Marschall, Brederoo, Ćurčić-Blake and Sommer 6 Improving vision diminishes the frequency of VRH.Reference Marschall, Brederoo, Ćurčić-Blake and Sommer 6 When feasible, reversal of deafferentation termed “reafferentation” is performed through surgical or medical interventions.Reference Rojas and Gurnani 1 , Reference Marschall, Brederoo, Ćurčić-Blake and Sommer 6 Therapeutic options can include excision of cataracts, diabetic retinopathy laser surgery, intravitreal ranibizumab for macular degeneration, etc.Reference Marschall, Brederoo, Ćurčić-Blake and Sommer 6 Visual pathway restoration through reafferentation can often curatively resolve VRH.Reference Rojas and Gurnani 1 -Reference Hamedani and Pelak 3

Pharmacological interventions

Medications for managing VRH vary.Reference Rojas and Gurnani 1 , Reference Hamedani and Pelak 3 , Reference Marschall, Brederoo, Ćurčić-Blake and Sommer 6 Antipsychotic drug treatments yield mixed results clinically; nevertheless, second-generation agents such as quetiapine or olanzapine are commonly prescribed.Reference Rojas and Gurnani 1 , Reference Hamedani and Pelak 3 , Reference Marschall, Brederoo, Ćurčić-Blake and Sommer 6 Their efficacy may be attributable to 5HT2A receptor antagonism as these receptors are concentrated in the visual cortex and are thought to be instrumental in the development of visual hallucinations.Reference Cummings, Devanand and Stahl 7

Small studies also report efficacy with cholinesterase inhibitors (e.g., donepezil), antiepileptic agents (e.g., valproate, carbamazepine, gabapentin, or clonazepam), serotonin reuptake inhibitors (e.g., escitalopram or venlafaxine), and the 5-HT4 receptor agonist cisapride.Reference Rojas and Gurnani 1

Behavioral & psychological interventions

Behavioral interventions are sometimes effective in mitigating VRH.Reference Rojas and Gurnani 1 , Reference Pang 2 Effective techniques include blinking, improving lighting conditions, rapidly moving eyes to concentrate on something outside the visual field &/or socializing with someone.Reference Rojas and Gurnani 1 , Reference Pang 2 Enhancing patient acceptance of VRH has also been found to improve prognosis & gradually reduce symptoms.Reference Marschall, Brederoo, Ćurčić-Blake and Sommer 6 Psychological interventions such as hypnosis, relaxation training, distraction therapies, cognitive remodeling, and psychotherapy have been shown to improve acceptance and coping with VRH.Reference Rojas and Gurnani 1

Neuromodulation

Enhancing inhibitory tone in the visual cortex through neuromodulation may hold promise for attenuating VRH. Repetitive transcranial magnetic stimulation (rTMS) may exert excitatory or inhibitory effects on specific target areas depending on the utilized technique.Reference Tang, Han, Wang, Zhang and Zhang 8 Inhibitory rTMS can be provided by low-frequency rTMS (LF-rTMS) or continuous theta-burst stimulation (cTBS).Reference Tang, Han, Wang, Zhang and Zhang 8 LF-rTMS has shown benefits for the management of some visual hallucinations and non-psychotic VRH.Reference Ghanbari, Naji and Nasr 9 -Reference Rafique, Richards and Steeves 11 However, the most promising treatment for VRH may be transcranial direct current stimulation (tDCS).Reference daSilva, Schumacher and Collerton 12 TDCS has already demonstrated level II evidence for reducing VRH specifically, and the portability of a tDCS device makes it an ideal tool for treating patients with VRH across a variety of practice settings.Reference daSilva, Schumacher and Collerton 12

VRH & psychosis

Most research on VRH has focused on non-psychotic manifestations encompassed under the diagnosis of CBS. Thus, VRH presenting in psychotic patients has not been thoroughly investigated. VRH in non-psychotic patients responds sub-optimally to pharmacological intervention alone; however, it is unknown whether VRH in psychotic patients responds similarly. It is also unclear if VRH can be detected in patients presenting with psychosis given the nature of CBS is not geared to detect VRH in psychotic populations. This paper reviews cases of possible VRH in genuinely psychotic patients and proposes that future emphasis of VRH should focus on visual release features.

Methods

A literature review was performed using keyword-based queries in the PubMed electronic database. The aim of this review was to identify case reports and case series where patients presented with suspected VRH in the absence of insight into their unreality. The review was conducted on April 01, 2023, and the search terms were: “Bonnet Psychosis”, “Charles Bonnet Plus”, “Atypical Charles Bonnet”, and “Release Hallucination”. Retrieval was limited to humans and publications after 1952. Duplicate reports and excluded studies were eliminated. Articles were included if they presented case reports or case series of patients experiencing visual hallucinations with a history of confirmed or suspected visual deafferentation. Then, texts were checked for eligibility criteria. Reviewers also examined the reference lists of eligible manuscripts to identify other possible sources. The final article selection encompassed cases of psychotic patients suspected of experiencing VRH. Patients were suspected of experiencing VRH if they developed hallucinations for the first time following vision loss or if there was a notable change in hallucination frequency or quality following vision loss. These VRH were considered psychotic if insight into the falsity of these perceptual disturbances was persistently absent.

The exclusion criteria were as follows.

  1. (1) The full article could not be obtained and the title or abstract contained insufficient information to determine if the patient is suspected of having experienced VRH.

  2. (2) A review of the full article suggested that patient(s) consistently had at least partial insight into the falsity of their perceptual disturbances and were not psychotic.

  3. (3) A review of the full article indicated that patient(s) had no confirmed visual deafferentation and therefore it was unclear if they were experiencing VRH.

  4. (4) A review of the full article implied that patient(s) presentation may be better explained by another condition.

  5. (5) The article did not contain patient-level data (Figure 2).

Figure 2. A search diagram showing the article selection and exclusion process.

Once eligible studies were identified, relevant data was extracted and entered into a database. Items collected were age, gender, type of visual hallucinations, cause of visual deafferentation, other psychiatric symptoms, cognitive status, medications, reafferentation techniques, and response to treatment. Delusions were listed under other psychiatric symptoms only if they extended beyond absent insight into the patients’ perceptual disturbances. Medication doses, if provided, are listed as the total daily dose. Clinical response was based on stated changes in VRH frequency. A “none” response meant that there was no notable change in hallucination frequency. A “partial” response indicated a reduction in frequency without complete disappearance. A “full” response inferred the complete resolution of VRH.

Results

In the initial search, 567 articles were identified, from which 519 were excluded. The remaining 48 papers were reviewed and 38 of these were removed. After searching the references of the remaining 10, an additional report was identified, providing 11 articles. All of them were case reports or case series, citing 13 individuals.

All cases either received pharmacological interventions, reafferentation therapy, or both. Table 2 summarizes the articles reviewed, including publication first author and year, patient age/gender, cause of visual deafferentation, visual hallucination type, other psychiatric symptoms, cognition, pharmacotherapies, reafferentation therapies, and treatment responses.

Table 2. Visual release hallucination case highlights

Data was analyzed to provide baseline epidemiological details and observations on treatment response by different methods. Table 3 summarizes the results obtained as follows. The mean age of psychotic patients with VRH was 70 years, with a median of 78 and a range between 9 and 90 years. Gender distribution was 9 males (69%) and 4 females (31%). Complex VRH were present in 12 cases (92%) and simple in 6 (46%); 5 cases (39%) reported both simple and complex VRH. Nine patients (69%) experienced delusions. Hallucinations in other sensory modalities were documented, with 2 patients (15%) experiencing auditory perceptions and 1 patient (8%) experiencing tactile hallucinations.

Table 3. Summary of case findings

Most cases (85%) reported cognitive status but barely a quarter (27%) verified this with reliable neurocognitive testing. Only 2 patients (18%) had a known or suspected cognitive impairment, with 9 (82%) considered unimpaired. It should be noted that the mini-mental status exam (MMSE) was not deemed to be a reliable neurocognitive testing measure for this study.

Response to treatment was determined by the author’s subjective reports. Responses to pharmacological agents were mixed: 4 (36%) denied improvement, 4 (36%) said there was some attenuation of VRH, and 3 (27%) reported full remission. All 4 subjects (100%) with visual reafferentation therapy achieved full remission. Overall, 7 patients (54%) achieved remission following treatment, leaving 3 (23%) with some progress, and 3 (23%) evidencing no improvement.

Discussion

VRH are a complex phenomenon whose prior study has predominantly focused on non-psychotic manifestations. While the original diagnostic criteria of CBS helped identify VRH thereby aiding investigations into their pathophysiology, this paradigm has limited ability to recognize VRH in psychotic patients. As this review shows, VRH likely contribute to psychosis in some populations. Still, though VRH may occur in psychotic patients, the validity of referring to these disturbances as VRH is not without problem. Even if a patient with a known hallucinatory condition develops vision loss and subsequently experiences a change in the nature or frequency of their hallucinations, who is to say that they are experiencing VRH rather than visual hallucinations with a multifactorial etiology?

Many individuals who experience vision loss never go on to develop visual hallucinations.(Reference Pang 2 , Reference Vojniković, Radeljak, Dessardo, Zarković-Palijan, Bajek and Linsak 5) A modern synthesis of 8 models for complex visual hallucinations has argued that visual hallucinations may be a consequence of multiple factors, and their episodic nature is better understood by integrating various models into a unified framework rather than considering them in isolation.Reference Collerton, Barnes and Diederich 24 Certainly, the episodic nature of VRH and its absence in many patients with profound vision loss highlights the importance of recognizing deafferentation as a part of the larger puzzle underlying visual perceptual disturbances.

However, this is not to undermine the importance of considering vision loss’s specific impact on visual hallucinations. Further research must be conducted to elucidate how vision loss impacts hallucinatory experiences and psychosis across all populations. It is possible that visual perceptual disturbances may be uniquely changed in individuals experiencing vision loss, factors which the authors’ term “visual release features”. Identifying these features may aid the recognition of vision loss in new populations and help guide clinical management. Treatment-resistant psychosis is a growing problem in our society.Reference Howes, Thase and Pillinger (25) With nearly 50 million people believed to experience VRH, under-recognition of deafferentation among patients experiencing visual hallucinations may be contributing to treatment resistance and suboptimal prognoses.Reference Subhi, Schmidt, Bach-Holm, Kolko and Singh (4) Reafferentation therapy, alternative pharmacological interventions, and neuromodulation may offer better clinical outcomes in patients experiencing hallucinations with release features.

To aid identification of visual release features among psychiatric populations, a preliminary visual release feature screening index (vRFI) has been provided in Table 4. This screening index is currently under review at our institution for empiric validation. Hopefully, improved recognition of visual release features will improve clinical outcomes for managing patients with treatment-resistant hallucinations and psychosis.

Table 4. Preliminary visual release feature screening index (vRFI)

Data availability statement

Additional data will be made available through correspondence with the corresponding author.

Acknowledgments

The authors would like to thank Dr. Andrew Francis MD, PhD, for mentorship.

Author contribution

Conceptualization: B.S., S.L., N.B.; Investigation: B.S., S.L., N.B.; Supervision: B.S., S.L., N.B.; Writing – review & editing: B.S., S.L.; Methodology: S.L., N.B.; Data curation: N.B.; Formal analysis: N.B.; Resources: N.B.; Writing – original draft: N.B.

Financial support

No extramural funding was provided to produce this manuscript.

Disclosure

The authors report no financial relationships in conflict with the production of this manuscript.

References

Rojas, LC, Gurnani, B. Charles Bonnet Syndrome; Statpearls Publishing, 2022. https://www.ncbi.nlm.nih.gov/books/NBK585133/. Accessed May 22, 2023.Google Scholar
Pang, L. Hallucinations experienced by visually impaired: Charles Bonnet syndrome. Optom Vis Sci. 2016;93(12):1466–1478.CrossRefGoogle ScholarPubMed
Hamedani, AG, Pelak, VS. The Charles Bonnet syndrome: a systematic review of diagnostic criteria. Curr Treat Options Neurol. 2019;21(9):41.CrossRefGoogle ScholarPubMed
Subhi, Y, Schmidt, DC, Bach-Holm, D, Kolko, M, Singh, A. Prevalence of Charles Bonnet syndrome in patients with glaucoma: a systematic review with meta-analyses. Acta Ophthalmol. 2021;99(2):128–133.CrossRefGoogle ScholarPubMed
Vojniković, B, Radeljak, S, Dessardo, S, Zarković-Palijan, T, Bajek, G, Linsak, Z. What associates Charles Bonnet syndrome with age-related macular degeneration? Coll Antropol. 2010;34 (2):45–48.Google ScholarPubMed
Marschall, TM, Brederoo, SG, Ćurčić-Blake, B, Sommer, IEC. Deafferentation as a cause of hallucinations. Curr Opin Psychiatry. 2020;33(3):206–211.CrossRefGoogle ScholarPubMed
Cummings, JL, Devanand, DP, Stahl, SM. Dementia-related psychosis and the potential role for primavanserin. CNS Spectr. 2022;27(1):7–15.CrossRefGoogle Scholar
Tang, Z, Han, K, Wang, R, Zhang, Y, Zhang, H. Excitatory repetitive transcranial magnetic stimulation over the ipsilesional hemisphere for upper limb motor function after stroke: a systematic review and meta-analysis. Front Neurol. 2022;13:918597.CrossRefGoogle ScholarPubMed
Ghanbari, JA, Naji, B, Nasr, EM. Repetitive transcranial magnetic stimulation in resistant visual hallucinations in a woman with schizophrenia: a case report. Iran J Psychiatry Behav Sci. 2016;10 (1):e3561.Google Scholar
Bodén, R, Nilsson, J, Walles, I, et al. Suppressing visual hallucinations in an adolescent by occipital transcranial magnetic stimulation: a single-case experimental research design. Neuropsychol Rehabil. 2023;33(2):346–355.CrossRefGoogle Scholar
Rafique, SA, Richards, JR, Steeves, JK. rTMS reduces cortical imbalance associated with visual hallucinations after occipital stroke. Neurology. 2016;87(14):1493–1500.CrossRefGoogle ScholarPubMed
daSilva, MK, Schumacher, J, Collerton, D, et al. Transcranial direct current stimulation in the treatment of visual hallucinations in Charles Bonnet syndrome: a randomized placebo-controlled crossover trial. Ophthalmology. 2022;129(12):1368–1379.CrossRefGoogle Scholar
Casey, DA, Wandzilak, T. Senile macular degeneration and psychosis. J Geriatr Psychiatry Neurol. 1988;1(2):108–109.CrossRefGoogle ScholarPubMed
Lanska, DJ, Lanska, MJ. Visual “release” hallucinations in juvenile neuronal ceroid-lipofuscinosis. Pediatr Neurol. 1993;9(4):316–317.CrossRefGoogle ScholarPubMed
Barnes, JJ. The Charles Bonnet syndrome: symptomatic relief with atypical neuroleptics: a case series. Int J Psychiatry Clin Pract. 2001;5(2):141–144.CrossRefGoogle ScholarPubMed
Jackson, ML, Ferencz, J. Cases: Charles Bonnet syndrome: visual loss and hallucinations. CMAJ. 2009;181(3–4):175–176.CrossRefGoogle ScholarPubMed
Makarewich, C, West, DA. Charles Bonnet syndrome-induced psychosis? Visual hallucinations with paranoid delusions in a visually-impaired man. J Neuropsychiatry Clin Neurosci. 2011; (4):E6.CrossRefGoogle Scholar
Arun, P, Jain, R, Tripathi, V. Atypical Charles bonnet syndrome. Indian J Psychol Med. 2013;35(4):402–404.CrossRefGoogle ScholarPubMed
Chatterjee, SS, Khonglah, D, Mitra, S, Garg, K. Gulliver’s world: Persistent lilliputian hallucinations as manifestation of Charles Bonnet syndrome in a case of cataract and normal pressure hydrocephalus. Indian J Psychiatry. 2018;60(3):358–360.CrossRefGoogle Scholar
Hill, F, Spurr, M, Stratford, J. Frightening complex visual hallucinations in an elderly patient with ophthalmological pathology and vascular dementia. Case Rep Psychiatry. 2020;2020:8851761.Google Scholar
Whitfield, NT, Krasniak, AE, Nguyen, HT. Concurrent delusions of ocular parasitosis and complex visual hallucinations from Charles Bonnet syndrome treated successfully with aripiprazole in an Elderly Male: a case report. Perm J. 2020;25:1–3.CrossRefGoogle Scholar
Maruzairi, H, Joo, CL. A case report on Charles Bonnet syndrome. Iran J Psychiatry. 2022;17(2):240–242.Google ScholarPubMed
Irizarry, R, Sosa Gomez, A, Tamayo Acosta, J, Gonzalez, DL. Charles Bonnet syndrome in the setting of a traumatic brain injury. Cureus. 2022;14(9):e29293.Google ScholarPubMed
Collerton, D, Barnes, J, Diederich, NJ, et al. Understanding visual hallucinations: a new synthesis. Neurosci Biobehav Rev. 2023;150:105208.CrossRefGoogle ScholarPubMed
Howes, OD, Thase, ME, Pillinger, T. Treatment resistance in psychiatry: state of the art and new directions. Mol Psychiatry. 2022;27(1):58–72.CrossRefGoogle ScholarPubMed
Figure 0

Table 1. Charles Bonnet syndrome criteria

Figure 1

Figure 1. A simplified model for a deafferentation injury. The top diagram depicts a normal visual pathway, and the bottom depicts a visual pathway with a deafferentation injury secondary to ocular pathology. The solid lines indicate an intact sensory pathway, while the dotted lines indicate deafferentation. Changes in blood flow (red arrow), metabolism (orange arrow) and excitability (yellow arrow) are denoted.

Figure 2

Figure 2. A search diagram showing the article selection and exclusion process.

Figure 3

Table 2. Visual release hallucination case highlights

Figure 4

Table 3. Summary of case findings

Figure 5

Table 4. Preliminary visual release feature screening index (vRFI)